Brokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) PT at $6.25

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $6.25.

A number of brokerages have recently issued reports on XERS. Wall Street Zen cut Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Piper Sandler reissued a "neutral" rating and issued a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Oppenheimer increased their target price on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. HC Wainwright reissued a "buy" rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Leerink Partners raised their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th.

Insider Buying and Selling

In other Xeris Biopharma news, insider Kevin Mcculloch acquired 25,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were purchased at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the purchase, the insider now directly owns 1,708,585 shares of the company's stock, valued at approximately $7,483,602.30. This represents a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.47% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. grew its position in Xeris Biopharma by 106.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company's stock worth $581,000 after buying an additional 88,224 shares in the last quarter. Vanguard Group Inc. grew its position in Xeris Biopharma by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock worth $26,778,000 after buying an additional 133,738 shares in the last quarter. Principal Financial Group Inc. grew its position in Xeris Biopharma by 10.5% during the fourth quarter. Principal Financial Group Inc. now owns 113,217 shares of the company's stock worth $384,000 after buying an additional 10,748 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Xeris Biopharma during the fourth quarter worth $45,000. Finally, Millennium Management LLC lifted its stake in Xeris Biopharma by 34.8% during the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock worth $6,606,000 after purchasing an additional 502,853 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS traded down $0.04 during mid-day trading on Friday, reaching $4.70. 4,686,329 shares of the company traded hands, compared to its average volume of 2,026,702. The stock has a market cap of $734.99 million, a PE ratio of -15.67 and a beta of 0.71. The company's fifty day moving average is $4.63 and its two-hundred day moving average is $4.20. Xeris Biopharma has a fifty-two week low of $2.03 and a fifty-two week high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. Research analysts forecast that Xeris Biopharma will post -0.41 earnings per share for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.